A significant proportion of patients with HER2-positive, ER-negative breast cancer can achieve a pathologic complete response after 12 weeks of THP chemotherapy. The trial identified ER-negative or low ER-expressing tumors, low or no progesterone receptor expression, HER2 IHC 3+ tumors, and weekly paclitaxel treatment as key predictors...
Dr. Dennis Slamon, a pioneer in breast cancer research, has been awarded the 2026 Albany Prize for his groundbreaking work on targeted cancer treatments. His discovery of the HER2 protein and the development of Herceptin have transformed the understanding and treatment of breast cancer, saving millions of lives worldwide.
The AFT-70 NAVIGATE trial tests a novel molecular residual disease-guided treatment strategy for ER-positive/HER2-negative breast cancer patients. The trial pairs giredestrant with longitudinal Signatera Genome MRD monitoring to identify patients who may benefit from treatment escalation with a CDK4/6 inhibitor.
The American College of Physicians recommends estrogen therapy as the first-line treatment for perimenopausal and postmenopausal women experiencing menopausal vasomotor symptoms, which include hot flashes and night sweats. For women without a uterus, estrogen monotherapy is also a viable option.
Researchers discovered a novel treatment combination that significantly improves progression-free survival in patients with ER-positive breast cancer. The study found that the combination of giredestrant and everolimus reduced the risk of disease progression by 44% in the ITT population and 63% in patients with ESR1 mutations.
A new study found a higher prevalence of prior breast cancer in patients with gallbladder cancer compared to patients with other biliary tract cancers. The association was observed in two independent cohorts, with 25.7% of patients with gallbladder cancer having a history of breast cancer.
A new driver of resistance in HR+ breast cancer has been identified through the discovery of FAH's nuclear role in stimulating CDK9 activity. This finding suggests a possible path to target resistant cancer cells and offers a new biomarker for resistance to CDK4/6 inhibitors.
A 12-month exercise intervention improved attention and memory in breast cancer survivors, while a companion study found exercise slowed epigenetic aging. These findings suggest exercise may help buffer against cognitive effects associated with accelerated epigenetic aging.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
A phase Ib/II trial evaluated the triple combination of famitinib, dalpiciclib, and fulvestrant in HR+/HER2− breast cancer, meeting initial efficacy targets with a confirmed objective response rate of 51.9%. However, the regimen showed no superiority over standard first-line treatments and was terminated early due to safety concerns.
A large Medicare analysis found that depression is associated with higher cancer mortality, while psychotherapy soon after diagnosis reduces cancer risk. Patients with depression had a 21% lower risk of cancer-specific mortality after receiving psychotherapy within four weeks of their diagnosis.
A large U.S. insurance claims analysis found that fewer than 30% of patients with hormone receptor-positive early-stage breast cancer remained adherent to endocrine therapy for five years after lumpectomy. Younger age and radiation therapy omission were associated with lower adherence rates.
Physicians in Türkiye are willing to order BRCA testing for eligible patients, but family participation and preventive care are lacking. A nationwide survey found that physician knowledge is the most influential factor in testing and screening recommendations.
A new trial will determine whether chemotherapy provides additional benefit for patients with high anatomic risk but low genomic risk. The RxFINE-Low trial will enroll 2,000 postmenopausal women and men with high anatomic risk breast cancer and low genomic risk, and follow them for up to 10 years.
A new study by Silent Spring Institute identified hundreds of chemicals in pesticide products that may increase breast cancer risk, including inert ingredients that evade safety testing. The study highlights a regulatory blind spot and calls for stronger oversight of pesticide formulations.
Researchers at Thomas Jefferson University found that women with high smoking histories and previous cancer diagnoses were more likely to be overdue for breast cancer screening. Integrating a simple reminder into lung cancer screening programs can address the 'critical gap in preventive care', increasing adherence to recommended screen...
A preclinical study found that SIRPα, a protein regulating immune cells, helps triple-negative breast cancer cells spread to the brain and weaken the immune response. Higher levels of SIRPα were associated with poorer outcomes in patients with TNBC, which is an aggressive form of breast cancer prone to brain metastasis.
A new AI-powered test, IICM+, has been developed to predict breast cancer recurrence risk more accurately than the widely used 21-gene Recurrence Score. IICM+ uses clinical, molecular, and histopathology data to provide reliable prognostic information, distinguishing between patients at different risks of recurrence.
The Alliance for Clinical Trials in Oncology is hosting a public webinar highlighting key findings from Alliance and Alliance Foundation Trials studies presented at the 2026 ASCO Annual Meeting. The webinar will feature treatment advances for breast, lung, and prostate cancers, and will include patient representatives to provide insigh...
A new study reanalysed data from eight randomised trials on mammography screening, finding overdiagnosis to be less than 5%. The researchers suggest that previous high estimates of overdiagnosis were based on incomplete evidence and taken out of context.
Researchers found that obesity prevents a biological process that kills cancerous cells, revealing a possible reason why obesity is a risk factor for breast cancer. The study discovered that a molecule called 9S-HODE, normally present in lean tissue, is less present in obese adipocytes, allowing cancerous cells to grow unchecked.
A new AI model, NYU-DRP, uses 3D mammograms to predict breast cancer risk, outperforming traditional methods. The tool correctly identified 72% of high-risk cases and reduced unnecessary screenings for those at lower risk.
Researchers found that methylglyoxal stress stimulates the expansion of immunosuppressive cells, which can help cancer evade immune surveillance. The study also identified a potential biomarker for predicting response to immunotherapy.
Massey researchers will evaluate TROP2 targeted ADCs for breast and pancreatic cancer care, aiming to identify predictive biomarkers and therapeutic strategies. The grant will help develop a test to predict patient drug response and identify secondary treatments for resistant tumors.
Fusobacterium nucleatum drives immunosuppression and metastasis in triple-negative breast cancer (TNBC) by reprogramming tryptophan metabolism and activating the IL4I1-dependent pathway, leading to reduced CD8+ T-cell infiltration and increased tumor growth, invasion, and pulmonary metastasis.
A review led by UCLA investigators found that AI can identify subtle signs of breast cancers missed during routine mammograms, but its clinical benefit is uncertain. AI may also identify patterns associated with an increased risk of cancer before it becomes visible on a mammogram.
A new study found that laws requiring notification of dense breast tissue led to modest increases in follow-up imaging tests, while insurance mandates had a significant impact, increasing ultrasound use four times. This study examined the influence of notification laws and insurance coverage independently.
Scientists at MUSC Hollings Cancer Center discovered a protein called lysyl oxidase that helps triple-negative breast cancer cells survive. Blocking LOX creates a weakness, which can be exploited with a second drug to block tumor growth without chemotherapy.
SUNY Chancellor King visited the Great New York State Fair, showcasing participating SUNY campuses and offering free admission to current and incoming students. The event highlights SUNY's agricultural, healthcare, and technology initiatives.
The study found that lifetime risk of developing breast cancer ranges from less than 1% in low-income countries to over 16% in wealthier nations. The risk of dying from breast cancer varies dramatically across regions, with very high HDI countries having the highest lifetime risk at 10.37%.
A new study from Karolinska Institutet suggests that breast cancer classification may overlook important biological differences between patients that could affect treatment decisions. Women with tumours having low to moderate levels of estrogen receptors have poorer survival rates, highlighting the importance of precise classification.
The Rice360 project, led by Rebecca Richards-Kortum, aims to develop a low-cost, AI-enabled system to accelerate breast cancer diagnosis in rural Texas. The system, Access BreastDX, uses an AI-enabled digital microscope to quickly scan breast cell and tissue samples, providing automated assessments and remote review by pathologists.
A new blood-based approach developed by Kumamoto University researchers detects breast cancer recurrence by analyzing nucleosome structure in circulating DNA. The study identified genomic regions associated with treatment resistance and recurrence, promising a low-invasive monitoring method for patients.
Researchers found that silencing POLG1 and POLG2 reduced mtDNA content, impaired mitochondrial function, and decreased stemness-related properties in breast cancer cells. POLG inhibition also suppressed colony formation and mammosphere growth, suggesting its potential as a therapeutic target and prognostic biomarker in breast cancer.
Researchers have identified a molecular switch driving the spread of aggressive triple-negative breast cancer, a subtype with poor outcomes. Restoring a naturally occurring molecule called miR-342 reduced metastatic disease in pre-clinical models.
Researchers developed a nanoplatform that addresses three barriers to TNBC immunotherapy by eliminating Tregs, destroying cancer cells, and activating innate immunity. In preclinical studies, the platform achieved 100% complete tumor regression and extended median survival beyond 70 days.
A telemedicine-supported home-injection model for patients with breast cancer has shown to reduce treatment burden by improving convenience and saving time. Most patients who completed home injections chose to continue this approach beyond the pilot, but barriers such as insurance denials and higher copayments may limit its broader imp...
A chemotherapy-free combination of targeted therapies showed encouraging results in patients with HR-positive, HER2-positive metastatic breast cancer, offering a potential first-line treatment option. The regimen produced durable responses while maintaining a manageable safety profile for many patients.
A nationwide claims data analysis in Japan found breast cancer survivors have a 1.57-fold higher risk of herpes zoster and a 1.70-fold higher risk of postherpetic neuralgia. Vaccination can reduce both the incidence of herpes zoster and the risk of complications, emphasizing the importance of prevention in breast cancer survivorship care.
The Alliance for Clinical Trials in Oncology emphasizes the significance of clinical trials in advancing breast cancer treatments and early detection. The organization's work has led to a 44% decline in breast cancer mortality rates among women since 1989.
Researchers discovered a 'master switch' driving tumour growth in aggressive breast cancer and a targeted drug slowing tumour growth. The drug reduced cancer cell viability and tumour growth by 40-60% and extended survival in laboratory models.
Researchers developed a new approach called SHIFTERS that uses focused ultrasound to temporarily 'light up' solid tumors, giving cancer-fighting immune cells a target they can recognize. The technology allows doctors to control where and when treatment switches on, potentially making solid tumors easier to treat.
Researchers developed a new 4D-printed breast cancer model that mimics the shape and movement of breast ducts. The study found that cancer cells behave differently when exposed to dynamic conditions, showing higher metabolic activity and greater survival after treatment with chemotherapy.
The study identified RTN4IP1 as a factor associated with poor prognosis in triple-negative breast cancer, promoting metastasis through NAD⁺ depletion and disrupting glycolysis and oxidative phosphorylation. RTN4IP1 interacts with AK4 to cause this metabolic disruption.
Researchers developed a method to predict how different types of breast cancer will respond to treatment using lab-grown mini tumors. The organoids mimicked a tumor's response to treatment and identified candidate combination therapies for cancers that don't respond to standard treatment.
Researchers at USC have developed a genetic tool called the Mechano-Recorder to measure tumor cell softness. This insight can help target hard-to-reach cancer stem-like cells for destruction, potentially improving cancer treatment outcomes.
A new study identified a previously underappreciated relationship between SUCLA2 and USP10 that strongly correlates with distant metastasis-free survival in breast cancer patients. The interaction between these two genes changes dramatically depending on whether patients receive treatment, highlighting the importance of considering mol...
A randomized clinical trial found that digital patient-reported outcome (PRO) monitoring with alert-based interventions led to clinically meaningful reductions in fatigue and improved physical functioning in metastatic breast cancer patients. This study supports further evaluation of PRO monitoring in routine oncology care.
A digital treatment concept, PRO B, combines close monitoring via an app with on-demand in-person care to alleviate fatigue and improve daily life for patients with metastatic breast cancer. The approach has been shown to reduce exhaustion, improve physical functioning, and decrease hospital visits.
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
A new wearable electric-field device has been shown to slow the growth and spread of aggressive breast cancer in preclinical models. The technology uses low-intensity electric fields that interact with cancer cells in a controlled way, reducing tumor growth and increasing immune responses.
Researchers discovered how breast tumors recruit immune cells to attract nerves that support tumor growth and treatment resistance. Blocking nerve growth may boost the immune response to fight cancer.
New research reveals that NICE referral criteria for breast cancer risk assessment miss up to 95% of women under 50 who go on to develop the disease within 10 years. A full risk assessment tool, BOADICEA, identifies eight times more women in this age group at higher risk.
A phase 2 clinical trial found that combining two immunotherapies with standard chemotherapy prior to surgery improved pathologic complete response rates in high-risk, early-stage HER2-negative breast cancer patients. The regimen demonstrated strong activity among patients with ImPrint-positive tumors, including high pCR rates.
Combining cemiplimab, fianlimab, and paclitaxel-based neoadjuvant chemotherapy improved pathologic complete response rates in high-risk -negative breast cancer. Patients with the ImPrint immune signature showed enhanced sensitivity to the combination.
Research highlights importance of cardiovascular care in breast cancer patients and survivors throughout life. Cardiovascular risk factors and interventions are essential to prevent disease progression and improve quality of life.
The grant supports the development of therapies with fewer side effects for triple-negative breast cancer, a highly aggressive and difficult-to-treat form of breast cancer. The researchers aim to target UBR5 protein, which is overproduced in aggressive breast cancers and several other malignancies.
The study found significant progress in reducing cancer mortality disparities for breast and uterine corpus cancers, but persistence in prostate cancer remains. The findings highlight the need for targeted interventions to accelerate progress in equitable cancer prevention and control.
A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, researchers reveal. The study found that replenishing beneficial bacteria or treating patients with FDA-approved bile acid sequestrants may reduce breast cancer metastasis.
Sylvester researchers develop AI-powered fracture prediction models, train as wildland firefighters to reduce cancer risk, and discover new targets for pancreatic cancer treatment. A new tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells.